Clinical Trials

NCT Number: NCT06067841 Phase: PHASE1 Trial Summary: The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT06016504 Phase: NA Trial Summary: This clinical trial aims to design and validate an adaptive virtual consultation tool (AVCT) for men with prostate cancer (PC). An AVCT utilizes health literacy assessments in combination with learnin – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT06016725 Phase: NA Trial Summary: This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-year – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: E-PROOF

NCT Number: NCT06018311 Phase: NA Trial Summary: The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

Patient Summary NCT Number: NCT05848011 Phase: PHASE2 Trial Summary: The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who received – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT05852041 Phase: EARLY_PHASE1 Trial Summary: This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT05884398 Phase: PHASE3 Trial Summary: The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: LIBERTAS

NCT Number: NCT05914116 Phase: PHASE1|PHASE2 Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT05917470 Phase: PHASE1|PHASE2 Trial Summary: A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer. The main questions it aims to answer are: * What a – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT05938270 Phase: PHASE1 Trial Summary: A Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN) – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: ASCERTAIN